A Review on Risk Factors,Staging and Survival Rates of Endometrial Cancer in Both Black and White Women in Infertility Patients in USA
This article is focused mainly on risk factors,staging and survival rates of endometrial cancer in infertility patients in both black and white women in United States, These risk factors split in to two groups such as exogenous& endogenous. Exogenous mainly (fertility treatment clomiphene, tamoxifen, human chorionic gonadotropins,human menopausal Gonadotropins& Birth control pills, intra uterine devices) These factors which increases the concentrations of unopposed estrogen for a short periods of time but successful leads to fertility, long-term leads to endometrial cancer, and endogenous risk factors includes mainly (Poly cystic ovary syndrome, Obesity,Diabetes, and Hypertension) these risk factors in infertility women may lead to increased unopposed estrogen in the body may leads to development of endometrial cancer over a period of time. It is the commonest reproductive cancer. Our objective was toassess association between exogenous and endogenous risk factors, in infertility patients staging and survival rates in infertility patients which leads to an endometrial cancer .It is estimated that by 2030, endo metrialcancer will become the 6th most common cancer overall, and the 3rd most common among women. In addition, five year survival after an EC diagnosis is lower for black women when compared to white women at every stage of diagnosis. “Early detection leads to early prevention”.
2. American Joint Committee on Cancer. Corpus Uteri-Carcinoma and Carcinosarcoma. In: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017:661-669.
3. Freeman SF et al. The Revised FIGO Staging System for Uterine Malignancies: Implications for MR Imaging. RadioGraphics. 2012; 32:1805–1827.
4. American Joint Committee on Cancer. Uterine Cancer. In: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010: 403-409.
5. Clinical green top guidelines. RCOG. 2007;33.
6. Cheung AP. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol. 2001;98:325–331.
7. Gopal M, Duntley S, Uhles M, Attarian H. The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovarian syndrome. Sleep Med. 2002;3:401–404.
8. Wild RA. Long term health consequences of PCOS. Hum Reprod Update. 2002;8:231–241.
9. Balen A, Rajkhowa R. Health consequences of polycystic ovary syndrome. In: Balen A, editor. Reproductive endocrinology for the MRCOG and beyond. 1st ed. London: RCOG press; 2003. pp. 99–107.
10. Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial cancer. Lancet. 2003;361:1810–1812.
11. Cho LW, Jayagopal V, Kilpatrick ES, Atkin SL. The biological variation of C-reactive protein in polycystic ovarian syndrome.
12. Wijeyaratne CN, Balen AH, Barth J, Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol. 2002;57:343–350.
13. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165–169.
14. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at longterm follow-up. J Clin Epidemiol. 1999;51:779–786.
15. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111:607–613.
16. Raikowha M, Glass MR, Rutherford AJ, Michelmore K, Balen AH. Polycystic ovary syndrome: a risk factor for cardiovascular disease? Br J Obstet Gynecol. 2000;107:11–18.
17. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111:607–613.
18. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and sympathoadrenal system. New Engl J Med. 1996:334–374. [PubMed]
19. 20. Cheang KI, Nestler JE, Futterweit W. Risk of cardiovascular events in mothers with polycystic ovary syndrome. Endocr Pract. 2008;14:1084–1094
20. Joint British Societies' guidelines. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(Suppl 5):v1–52.
21. Rose PG (1996) Endometrial carcinoma.N Engl J Med 335: 640-649.
22. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, et al. (2005) Risk factors for young premenopausal women with endometrial cancer.ObstetGynecol 105: 575-580.
23. Gallup DG, Stock RJ (1984) Adenocarcinoma of the endometrium in women 40 years of age or younger.ObstetGynecol 64: 417-420.